NEW YORK (GenomeWeb) – Wells Fargo today upgraded shares of Myriad Genetics, saying its hereditary cancer testing business has stabilized after a period of market share loss. 

In a research note, analyst Tim Evans upgraded Myriad to an Outperform rating from a prior Market Perform rating and raised the price range on the firm's stock to between $36 and $38 from a previous range of $33 to $34. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.